Department of Hematology-Oncology, CHU-Notre Dame de Secours, Byblos, Lebanon
Case Report
Azacitidine Combined With Low Dose Venetoclax and Azole in Treatment-Naive, Elderly Patient with Acute Myeloid Leukemia: A Case Report
Author(s): Zeghondy J*, Sakr R and Massoud M
We report the case of a 70-year-old frail patient with AML-M0, normal
karyotype and negative FLT3 and NPM1, treated successfully with
the combination of Azacitidine (75 mg/m2 D1-D7) and Venetoclax
(100 mg D1-D14) in whom Fluconazole was added to potentiate
the effect of Venetoclax in vivo, reaching a Complete Remission.
Venetoclax is metabolized by the CYP3A. When administered with
strong CYP3A inhibitors, such as azoles, drug’s concentration
will increase by 2-7 folds empowering its effect. Considering the
inadequate accessible dose of Venetoclax and the current Lebanese
economic crisis, 200 mg of daily Fluconazole, a moderate CYP3A4 inhibitor, was combined to Venetoclax to increase its bioavailability.
The patient reached a complete remission after four cycles. He
presented grade I febrile neutropenia after.. View More»
DOI:
10.35248/2471-8556.20.6.001-003